Peter Greenleaf - Net Worth and Insider Trading
Peter Greenleaf Net Worth
The estimated net worth of Peter Greenleaf is at least $11 Million dollars as of 2024-10-06. Peter Greenleaf is the CEO of Aurinia Pharmaceuticals Inc and owns about 1,522,114 shares of Aurinia Pharmaceuticals Inc (AUPH) stock worth over $11 Million. Peter Greenleaf is the CEO of Sucampo Pharmaceuticals Inc and owns about 2,513 shares of Sucampo Pharmaceuticals Inc (SCMP) stock worth over $45,234. Peter Greenleaf is also the CEO of Avalo Therapeutics Inc and owns about 143 shares of Avalo Therapeutics Inc (AVTX) stock worth over $1,397. Details can be seen in Peter Greenleaf's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Peter Greenleaf has not made any transactions after 2024-03-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Peter Greenleaf
Peter Greenleaf Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Peter Greenleaf owns 8 companies in total, including BioDelivery Sciences International Inc (BDSI) , Antares Pharma Inc (ATRS) , and Avalo Therapeutics Inc (AVTX) among others .
Click here to see the complete history of Peter Greenleaf’s form 4 insider trades.
Insider Ownership Summary of Peter Greenleaf
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
BDSI | BioDelivery Sciences International Inc | 2020-08-07 | director |
ATRS | Antares Pharma Inc | 2022-05-24 | director |
AVTX | Avalo Therapeutics Inc | 2018-05-18 | director & Chief Executive Officer |
2018-07-10 | director | ||
2018-02-13 | Chief Executive Officer | ||
2015-11-05 | director | ||
2016-03-01 | director | ||
2024-03-06 | director & Chief Executive Officer |
Peter Greenleaf Latest Holdings Summary
Peter Greenleaf currently owns a total of 3 stocks. Among these stocks, Peter Greenleaf owns 1,522,114 shares of Aurinia Pharmaceuticals Inc (AUPH) as of March 6, 2024, with a value of $11 Million and a weighting of 99.57%. Peter Greenleaf owns 2,513 shares of Sucampo Pharmaceuticals Inc (SCMP) as of November 29, 2016, with a value of $45,234 and a weighting of 0.42%. Peter Greenleaf also owns 143 shares of Avalo Therapeutics Inc (AVTX) as of May 18, 2018, with a value of $1,397 and a weighting of 0.01%.
Latest Holdings of Peter Greenleaf
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
AUPH | Aurinia Pharmaceuticals Inc | 2024-03-06 | 1,522,114 | 7.12 | 10,837,452 |
SCMP | Sucampo Pharmaceuticals Inc | 2016-11-29 | 2,513 | 18.00 | 45,234 |
AVTX | Avalo Therapeutics Inc | 2018-05-18 | 143 | 9.77 | 1,397 |
Holding Weightings of Peter Greenleaf
Peter Greenleaf Form 4 Trading Tracker
According to the SEC Form 4 filings, Peter Greenleaf has made a total of 5 transactions in Aurinia Pharmaceuticals Inc (AUPH) over the past 5 years, including 1 buys and 4 sells. The most-recent trade in Aurinia Pharmaceuticals Inc is the sale of 126,981 shares on March 6, 2024, which brought Peter Greenleaf around $711,094.
According to the SEC Form 4 filings, Peter Greenleaf has made a total of 0 transactions in Sucampo Pharmaceuticals Inc (SCMP) over the past 5 years. The most-recent trade in Sucampo Pharmaceuticals Inc is the sale of 200,000 shares on November 29, 2016, which brought Peter Greenleaf around $3 Million.
According to the SEC Form 4 filings, Peter Greenleaf has made a total of 0 transactions in Avalo Therapeutics Inc (AVTX) over the past 5 years. The most-recent trade in Avalo Therapeutics Inc is the acquisition of 4 shares on May 18, 2018, which cost Peter Greenleaf around $49,750.
Insider Trading History of Peter Greenleaf
- 1
Peter Greenleaf Trading Performance
GuruFocus tracks the stock performance after each of Peter Greenleaf's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Peter Greenleaf is 34.19%. GuruFocus also compares Peter Greenleaf's trading performance to market benchmark return within the same time period. The performance of stocks bought by Peter Greenleaf within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Peter Greenleaf's insider trading performs compared to the benchmark.
Performance of Peter Greenleaf
Peter Greenleaf Ownership Network
Peter Greenleaf Owned Company Details
What does BioDelivery Sciences International Inc do?
Who are the key executives at BioDelivery Sciences International Inc?
Peter Greenleaf is the director of BioDelivery Sciences International Inc. Other key executives at BioDelivery Sciences International Inc include See Remarks James Vollins , See Remarks Mary Theresa Coelho , and director & Chief Executive Officer Jeffrey Allen Bailey .
BioDelivery Sciences International Inc (BDSI) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of BioDelivery Sciences International Inc (BDSI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of BioDelivery Sciences International Inc (BDSI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
BioDelivery Sciences International Inc (BDSI)'s detailed insider trading history can be found in Insider Trading Tracker table.
BioDelivery Sciences International Inc Insider Transactions
Peter Greenleaf Mailing Address
Above is the net worth, insider trading, and ownership report for Peter Greenleaf. You might contact Peter Greenleaf via mailing address: One Medimmune Way, Gaithersburg Md 20878.